U.S. markets closed
  • S&P Futures

    4,564.75
    -0.50 (-0.01%)
     
  • Dow Futures

    35,642.00
    -2.00 (-0.01%)
     
  • Nasdaq Futures

    15,532.50
    -12.50 (-0.08%)
     
  • Russell 2000 Futures

    2,290.10
    -3.80 (-0.17%)
     
  • Crude Oil

    84.10
    -0.55 (-0.65%)
     
  • Gold

    1,792.60
    -0.80 (-0.04%)
     
  • Silver

    24.12
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1605
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6190
    -0.0160 (-0.98%)
     
  • Vix

    15.98
    +0.74 (+4.86%)
     
  • GBP/USD

    1.3773
    +0.0010 (+0.07%)
     
  • USD/JPY

    114.0800
    -0.0490 (-0.04%)
     
  • BTC-USD

    60,720.08
    -2,083.53 (-3.32%)
     
  • CMC Crypto 200

    1,471.79
    -33.36 (-2.22%)
     
  • FTSE 100

    7,277.62
    +54.80 (+0.76%)
     
  • Nikkei 225

    28,942.59
    -163.42 (-0.56%)
     

BioDelivery Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RALEIGH, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020. The company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:

Thursday, March 12, 2020

Time:

4:30 PM Eastern Time

Domestic:

877-407-0789

International:

201-689-8562

Conference ID:

13699178

Webcast:

http://public.viavid.com/index.php?id=138131

About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain, opioid dependence, and opioid-induced constipation.

© 2020 BioDelivery Sciences International, Inc. All rights reserved.

Contact:
Tirth T. Patel
Director of Investor Relations
tpatel@bdsi.com
(919) 582-0294